Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Natera ( (NTRA) ).
On June 12, 2025, Natera, Inc. held its Annual Meeting of Stockholders, where an amendment to the 2015 Equity Incentive Plan was approved, increasing the shares reserved for issuance by 3.6 million. This decision, along with the election of directors and ratification of Ernst & Young LLP as the accounting firm, reflects Natera’s strategic focus on enhancing its equity structure and governance.
The most recent analyst rating on (NTRA) stock is a Buy with a $157.00 price target. To see the full list of analyst forecasts on Natera stock, see the NTRA Stock Forecast page.
Spark’s Take on NTRA Stock
According to Spark, TipRanks’ AI Analyst, NTRA is a Neutral.
Natera’s overall stock score reflects strong financial performance and an optimistic outlook from the recent earnings call, which partially offsets valuation concerns due to ongoing losses. Technical indicators show modest short-term momentum but are not strong enough to significantly boost the score.
To see Spark’s full report on NTRA stock, click here.
More about Natera
Natera, Inc. operates in the biotechnology industry, focusing on genetic testing and diagnostics. The company provides services primarily in prenatal testing, oncology, and organ transplantation, aiming to offer insights into genetic conditions and diseases.
Average Trading Volume: 1,361,396
Technical Sentiment Signal: Buy
Current Market Cap: $22.97B
For detailed information about NTRA stock, go to TipRanks’ Stock Analysis page.